血清sRANKL/OPG在术前评价肺腺癌淋巴转移中的价值

Value of serum sRANKL and OPG in evaluating lymphatic metastasis of lung adenocarcinoma

目的探讨可溶性核因子κB受体活化因子配体/护骨素(sRANKL/OPG)在术前评价肺腺癌淋巴转移中的价值。方法采用ELISA试验检测肺腺癌有淋巴转移的58例(A组)患者和无淋巴转移的50例(B组)术前血清中OPG和sRANKL的水平。结果 A组血清sRANKL水平及sRANKL/OPG比值均高于B组(P<0.01)。最佳截断点血清sRANKL(>5.54pmol/L)诊断肺腺癌淋巴转移的敏感性、特异性和正确率分别为75.9%、76.0%和75.9%,而sRANKL/OPG比值(>0.80)的敏感性、特异性和正确率分别为77.6%、84.0%和80.6%。结论血清sRANKL水平和sRANKL/OPG比值可作为术前评价肺腺癌淋巴转移的辅助临床指标。

Objective To explore the value of serum soluble receptor activator of nuclear factor rB ligand （sRANKL） and osteoprotegerin （OPG） in evaluating lymphatic metastasis of lung ad ad Methods Serum OPG and sRANKL levels were determined by ELISA in lung patients with lymphatic metastasis （group A, 58 cases） and lung ad patients without lymphatic metastasis（group B,50 cases）. Results Serum levels of sRANKL and the ratio of sRANKL to OPG were higher in group A than those in group B（P〈0. 01）. Taking sRANKL 〉5.54 pmol/L as a cut-off value, the sensitivity, specifcity and accuracy in predicting lymphatic metastasis of lung adenocarcinoma patients were 75.9%, 76.0% and 75. 9%, respectively. Taking the ratio of sRANKL to OPG 〉 0.80 as a cut-off value, the sensitivity, specificity and accuracy in predicying lymphatic metastasis were 77.6 %, 84.0% and 80. 6 %, respectively. Conclusion OPG/ RANKL system may be associated with the lymphatic metastasis of lung adenocarcinoma, The ratio serum sRANKL to OPG can be a promising auxiliary clinical index in evaluating lymphatic metastasis of lung adenocarcinoma patients before surgery.